What happens when patient organisations help shape clinical trials and why the right CRO partner makes that collaboration work.

Clinical trial consent documents are long for good reason. They must meet strict ethical, scientific and regulatory requirements. Their complexity reflects a system designed to protect participants. But the people these documents are meant to protect do not always experience them that way. A participant with a rare condition who has waited years for a potential treatment still has to navigate dense clinical and legal language before agreeing to take part. The visit schedule may be scientifically necessary but practically demanding. The endpoints may be clinically validated but disconnected from outcomes the participant recognises in daily life.

None of this reflects poor intent. It reflects a design process in which the patient perspective is often among the last to arrive, and where the cumulative burden of participation can quietly erode retention.

What patient organisations bring to protocol design

Protocol design is a multidisciplinary process, from clinical scientists that bring therapeutic depth and methodological rigour to biostatisticians defining the analytical framework or regulatory specialists ensuring compliance with regulatory requirements.

What this collective expertise does not always include is structured input from the people who will live with the protocol’s demands. Patient advocacy organisations can bridge that gap: they bring an understanding of what daily life looks like with a given condition, which visit schedules are practically sustainable and which endpoints reflect the outcomes that matter most to the people the treatment is designed to help.

This collaboration matters most where the stakes are highest. In rare diseases, patient populations are small and widely dispersed. Equally, in any therapeutic area where recruitment is known to be challenging, early engagement with patient organisations can surface practical barriers that would otherwise only become visible once enrolment is underway and far more costly to address.

When advocacy organisations are involved early in protocol development, their input tends to concentrate in the areas most likely to affect feasibility and retention: whether the endpoints selected align with outcomes patients recognise as meaningful, whether the visit schedule is sustainable alongside the realities of managing a chronic condition, and whether consent materials communicate effectively without sacrificing regulatory completeness. This is not about overriding scientific or regulatory judgement. It is about adding a structured layer of practical intelligence that complements them.

Published evidence supports this. Analysis of approximately 50 patient advisory boards run by CISCRP found that each produced concrete, actionable recommendations for protocol changes.⁴ The FDA’s Patient-Focused Drug Development guidance series, now three documents into a planned four, reflects the agency’s own recognition that systematically incorporating the patient perspective into development can strengthen both trial design and regulatory decision-making.

Retention begins at the protocol. If the design does not account for the reality of participants’ lives, no recruitment strategy will compensate.

Why the CRO you choose affects how well co-design works

Most CROs now reference patient centricity as a core capability. The difference between organisations lies less in intent than in structure: specifically, at what stage patient and advocacy group input enters the process and how directly it can influence protocol design decisions. In larger, more layered organisations, patient engagement functions sometimes sit apart from the clinical design team, which can mean that feedback from advocacy groups reaches decision-makers only after the protocol is substantially locked.

The question for sponsors is not whether a CRO values the patient voice in principle, but whether its operating model allows patient and advocacy group input to reach the people designing the study early enough to act on it. When study design, regulatory strategy and engagement sit in separate functions with independent approval chains, even strong feedback can struggle to translate into protocol-level change.

What makes patient groups co-design work at TFS

This article reflects TFS HealthScience’s approach to patient group engagement in clinical trial design. It is intended for informational purposes and does not reference any specific sponsor, study or confidential programme. Regulatory references are based on publicly available ICH and FDA guidance documents.

TFS HealthScience is a global contract research organisation with deep specialisation in dermatology, internal Medicine, Neuroscience, Oncology and Ophthalmology. With a flat, senior-led structure and teams that stay with programmes from start to finish, TFS partners with biotechnology and pharmaceutical companies who want scientific authority, operational speed and a CRO that treats their molecule as its own.

Sources

1. Getz KA, Stergiopoulos S, Short M et al. New benchmarks on protocol amendment practices, trends and their impact on clinical trial performance. Tufts CSDD, 2023. Presented at SCOPE Summit 2024.
2. Getz KA, Stergiopoulos S, Short M et al. “The Impact of Protocol Amendments on Clinical Trial Performance and Cost.” Therapeutic Innovation & Regulatory Science, 2016; 50(4):436–441.
3. Getz KA, Wenger J, Campo RA et al. “Improving Protocol Design Feasibility to Drive Drug Development Economics and Performance.” Therapeutic Innovation & Regulatory Science, 2014; 48(1):7–15.
4. Anderson A, Getz KA. “Using Patient Advisory Boards to Solicit Input Into Clinical Trial Design and Execution.” Clinical Therapeutics, 2019; 41(8):1408–1413.